Literature DB >> 8127098

Results of left ventricular aneurysmectomy with a tailored scar excision and primary closure technique.

L L Mickleborough1, H Maruyama, P Liu, S Mohamed.   

Abstract

Controversy exists concerning which surgical technique is optimal for ventricular aneurysm repair. In 92 (97%) of 95 patients, we tailored scar excision to remove nonfunctioning wall and restore left ventricular geometry and shape toward normal while allowing linear closure. Preoperative and/or postoperative multiple gated acquisition scans were obtained in 76 (83%) of 92 patients and Doppler echocardiograms in 79 (86%) of 92. Before operation 78 patients (85%) were in New York Heart Association class III or IV with congestive heart failure in 58 (63%), angina in 69 (75%) and syncope in 46 (50%) of the 92 patients. Additional operative procedures included aorta-coronary bypass grafting in 81 patients (88%), septoplasty in 4 (4%), and arrhythmia ablation in 54 (59%). Hospital mortality was 3 (3%) of 92 patients. There have been 15 late deaths caused by congestive heart failure with or without mitral regurgitation (7 of 15). Among survivors 66 (89%) of 74 were symptomatically improved with 25 (34%) of 74 in New York Heart Association class I, 24 (32%) of 74 in class II, 19 (26%) of 74 in class III, and 6 (8%) of 74 in class IV. Actuarial survival was 88%, 86%, and 80% at 1, 2, and 5 years, respectively, and was not different for patients with a preoperative left ventricular ejection fraction less than 20%. In 47 patients with an anterior aneurysm who had preoperative and postoperative studies, multiple gated acquisition scans showed improvement in left ventricular ejection fraction from 23% to 30% (p < 0.001). Preoperative Doppler echocardiograms showed significant mitral regurgitation (2+ or more) in 26 (36%) of 72 patients studied. Of these, 21 had postoperative studies and mitral regurgitation was improved by at least one grade in 12 (57%) of 21 patients. We conclude that aneurysm repair with a tailored scar excision and linear closure is associated with low operative mortality, objective evidence of improvement in left ventricular function, symptomatic relief, and long-term survival even in patients with advanced left ventricular dysfunction and mitral regurgitation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8127098

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  Surgical repair of mechanical complications of myocardial infarction.

Authors:  Malek G Massad; Alexander S Geha
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

Review 2.  Architecture of the left ventricle: insights for optimal surgical ventricular restoration.

Authors:  Srilakshmi M Adhyapak; V Rao Parachuri
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

3.  Left ventricle remodelling by double-patch sandwich technique.

Authors:  Ernesto Tappainer; Vinicio Fiorani; Nicola Pederzolli; Jacopo Manfredi; Andrea Nocchi; Mario Zogno
Journal:  J Cardiothorac Surg       Date:  2007-01-31       Impact factor: 1.637

4.  The Effects of Levosimendan and Sodium Nitroprusside Combination on Left Ventricular Functions After Surgical Ventricular Reconstruction in Coronary Artery Bypass Grafting Patients.

Authors:  Zeki Temizturk; Davut Azboy; Atakan Atalay; Hakan Atalay; Omer Faruk Dogan
Journal:  Open Cardiovasc Med J       Date:  2016-06-30

5.  Left Ventricular Reconstruction Surgery in Candidates for Heart Transplantation.

Authors:  Carlos Alberto Méndez Contreras; Pedro Xavier Orellana; Antonio Flávio Sanchez de Almeida; Marco Aurélio Finger; João Manoel Rossi; Paulo Chaccur
Journal:  Braz J Cardiovasc Surg       Date:  2019-06-01

6.  Early results after surgical treatment of left ventricular aneurysm.

Authors:  Xisheng Wang; Xuezhi He; Yunqing Mei; Qiang Ji; Jing Feng; Jianzhi Cai; Yifeng Sun; Shiliang Xie
Journal:  J Cardiothorac Surg       Date:  2012-11-21       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.